PRGO

Perrigo

PRGO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,511

Bullish sentiment (50-day avg)93%

Price to earnings ratio2.8K

Market capitalization2.1B

Earnings per share-12.3

Dividend yield (TTM)7.69%

Revenue (annual)4.3B

Net income (annual)-1.4B

Social

What share of all stock conversation is about PRGO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Aug 5

Perrigo Company plc ($PRGO) reported a mixed Q2 2026, with EPS of $0.63 reversing a prior-year loss, despite a gain from the Dermacosmetics divestiture.
Perrigo beats 2Q estimates, reaffirms 2026 outlook, and shares rise +25%, with investors evaluating long-term opportunities and potential catalysts.
Perrigo's Q2 adjusted EPS reached $0.50, crushing analyst expectations of $0.31, with market share gains on the company's broad portfolio of quality self-care products.

Generated by AI

Sentiment

Of the messages about PRGO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +8.82	75.09% +2.14
Bearish	—	0% 0	0% -8.82	24.91% -2.14

Bullish· Sep 30

Perrigo Company plc ($PRGO) shares are trading higher after resolving the Irish tax assessment for €297 million, with a 14% gain in premarket trading.
Jefferies analyst David Steinberg upgraded $PRGO to Buy with a $63 price target, citing the resolved tax assessment as a key factor.
The resolved tax assessment and upgrade by Jefferies have prompted a significant increase in $PRGO's stock price, with a 14.2% gain in premarket trading.

Bearish· Dec 21

$PRGO faces a significant tax bill of $1.87 billion from Irish tax authorities, contributing to its decline.
The company's share price has dropped 25% today, 37% for the month, and 55% for the year, with the latest blow being the tax bill.
Perrigo's shares are trading lower due to uncertainty surrounding the tax liabilities, with some investors potentially selling their stakes, leading to a further 30% drop in price.

Generated by AI

Topics

Of the messages about PRGO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	81.82%	22.45%
Announcements	—	0%	0%	12.01%
Macro	—	0%	18.18%	59.27%
Analysts	—	0%	0%	2.35%
Controversies	—	0%	0%	0.26%
Earnings	—	0%	0%	3.66%

Earnings· May 9

Perrigo Company plc ($PRGO) reported Q1 non-GAAP EPS of $0.45, beating estimates by $0.02.
The company's revenue of $1.18B also exceeded expectations.
Perrigo updated its FY23 guidance to $2.50-$2.70 EPS and revenue guidance to $4.76-$4.94 billion.

Analysts· Sep 30

Jefferies upgraded PRGO to Buy with a $63 price target, sending shares up 13% in premarket trading.
The upgrade was due to Perrigo resolving the Irish tax assessment for €297 million, a significant positive development for the company.
Jefferies analyst David Steinberg raised the price target from $45 to $63, citing the tax resolution as a key factor in the upgrade.

Announcements· Jul 13

Perrigo Company plc's ($PRGO) stock surges 5.5% on FDA approval of Opill, an over-the-counter daily oral contraceptive.
The FDA has approved Opill, a progestin-only daily oral contraceptive, for over-the-counter use in the US, marking the first time a birth control pill has received such approval.
Perrigo's shares are trading higher after the company announced it received FDA approval for Opill, an OTC daily oral contraceptive, with some reports indicating a 6% increase in stock price.

Controversies· May 3

Perrigo Company plc's offices were raided by federal agents as part of a price-collusion investigation, causing its stock to drop 6%.
The investigation is related to allegations of price-fixing in the generic drug market, with Perrigo's stock also down 26% since a report highlighted corporate governance issues.
Perrigo has announced a dividend for shareholders, despite the negative news, with some analysts suggesting the DOJ investigation may be an attempt to extort the company.

Macro· Apr 20

Perrigo, a US-based OTC API provider, could benefit from tariffs on imported pharmaceuticals driving domestic production.
Companies with US-based manufacturing, such as Perrigo, may see an increase in demand if tariffs lead to a shift in production from abroad.
Pharmaceutical companies with both domestic and global manufacturing operations, like Pfizer and Merck, may be less impacted by tariffs due to their diversified supply chains.

Technical Analysis· Apr 26

Perrigo Company plc ($PRGO) failed to follow through on momentum, and its price is below its Chandelier Exit of $117.77.
The stock has reached oversold levels, with a 1-month RSI of 21, and is expected to bounce back to $104 before another drop.
Technical indicators, including Expansion Breakdown, Stochastic Reached Oversold, and Wide Range Bar, suggest a potential breakdown in the stock's price, with a target of $89 or lower.

Generated by AI

Community

Of the messages about PRGO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	16%	32.05%	24.94%
Newcomers	0%	84%	67.95%	75.06%

Regulars· Feb 27

Perrigo Company plc has hiked its dividend for the 21st consecutive year, with annual hikes of 1.1%, 5.0%, 8.3%, and 6.7% in the last four years.
Despite reporting better-than-expected financials for Q4 2023, Perrigo's shares lost ~15% on Tuesday due to disappointing outlook amid plans to implement a cost-cutting initiative.
Perrigo reports FQ4 earnings of 86c EPS and $1.16B Revs, but misses the Estimize Revenue Consensus by $17.14M and beats the Estimize EPS Consensus by 4c.

Newcomers· Feb 27

Perrigo Company plc is expecting to lay off approximately 550 employees, roughly 6% of its total staff.
Perrigo has continued its dividend growth streak, marking 21 years of consecutive increases, with a 1.1% hike in 2024.
The company reported Q4 2023 sales missing estimates and guidance for flat reported net sales in 2024, leading to a stock decline of over 15%.

Generated by AI

Perrigo (PRGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

5d agoYahoo Finance

Also Discussed

Investors talking about PRGO also mention

#	Name	Attention
1	Teva Pharmaceutical Industries Ltd. ADRTEVA	0%0
2	TARO - Taro Pharmaceutical Industries Ltd.	——
3	HZNP - Horizon Therapeutics Public Limited Company	——
4	Incyte Corp.INCY	0%new
5	Check Point Software Technologies LtdCHKP	0%new
6	PDCO - Patterson Companies, Inc.	——
7	Ionis Pharmaceuticals, Inc.IONS	0%new
8	Silgan Holdings Inc.SLGN	0%0
9	OMIC - Singular Genomics Systems, Inc.	——
10	Phibro Animal Health Corporation Class A Common StockPAHC	0%0

Perrigo Company plc

Healthcare
Drug Manufacturers - Specialty & Generic

Perrigo Company plc is a consumer health company that develops, manufactures, and markets self-care products and over-the-counter health and wellness solutions. Its portfolio spans products for everyday needs such as pain relief, digestive health, allergy care, cough and cold, nutrition, and infant care, serving consumers through branded and store-brand offerings. The company also participates in selected prescription pharmaceutical and active ingredient businesses, giving it a broader presence across healthcare supply chains. Perrigo Company plc focuses on accessible, self-managed healthcare products that are distributed across the United States, Europe, and other international markets. Headquartered in Dublin, Ireland, Perrigo Company plc plays a significant role in the consumer health market by supplying large retailers, pharmacies, and healthcare channels with products designed for routine, non-prescription use.

Website

Location

The Sharp Building

Dublin, MI, D02 TY74

Ireland

Social

What share of all stock conversation is about PRGO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Aug 5

Perrigo Company plc ($PRGO) reported a mixed Q2 2026, with EPS of $0.63 reversing a prior-year loss, despite a gain from the Dermacosmetics divestiture.
Perrigo beats 2Q estimates, reaffirms 2026 outlook, and shares rise +25%, with investors evaluating long-term opportunities and potential catalysts.
Perrigo's Q2 adjusted EPS reached $0.50, crushing analyst expectations of $0.31, with market share gains on the company's broad portfolio of quality self-care products.

Generated by AI

Sentiment

Of the messages about PRGO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +8.82	75.09% +2.14
Bearish	—	0% 0	0% -8.82	24.91% -2.14

Bullish· Sep 30

Perrigo Company plc ($PRGO) shares are trading higher after resolving the Irish tax assessment for €297 million, with a 14% gain in premarket trading.
Jefferies analyst David Steinberg upgraded $PRGO to Buy with a $63 price target, citing the resolved tax assessment as a key factor.
The resolved tax assessment and upgrade by Jefferies have prompted a significant increase in $PRGO's stock price, with a 14.2% gain in premarket trading.

Bearish· Dec 21

$PRGO faces a significant tax bill of $1.87 billion from Irish tax authorities, contributing to its decline.
The company's share price has dropped 25% today, 37% for the month, and 55% for the year, with the latest blow being the tax bill.
Perrigo's shares are trading lower due to uncertainty surrounding the tax liabilities, with some investors potentially selling their stakes, leading to a further 30% drop in price.

Generated by AI

Topics

Of the messages about PRGO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	81.82%	22.45%
Announcements	—	0%	0%	12.01%
Macro	—	0%	18.18%	59.27%
Analysts	—	0%	0%	2.35%
Controversies	—	0%	0%	0.26%
Earnings	—	0%	0%	3.66%

Earnings· May 9

Perrigo Company plc ($PRGO) reported Q1 non-GAAP EPS of $0.45, beating estimates by $0.02.
The company's revenue of $1.18B also exceeded expectations.
Perrigo updated its FY23 guidance to $2.50-$2.70 EPS and revenue guidance to $4.76-$4.94 billion.

Analysts· Sep 30

Jefferies upgraded PRGO to Buy with a $63 price target, sending shares up 13% in premarket trading.
The upgrade was due to Perrigo resolving the Irish tax assessment for €297 million, a significant positive development for the company.
Jefferies analyst David Steinberg raised the price target from $45 to $63, citing the tax resolution as a key factor in the upgrade.

Announcements· Jul 13

Perrigo Company plc's ($PRGO) stock surges 5.5% on FDA approval of Opill, an over-the-counter daily oral contraceptive.
The FDA has approved Opill, a progestin-only daily oral contraceptive, for over-the-counter use in the US, marking the first time a birth control pill has received such approval.
Perrigo's shares are trading higher after the company announced it received FDA approval for Opill, an OTC daily oral contraceptive, with some reports indicating a 6% increase in stock price.

Controversies· May 3

Perrigo Company plc's offices were raided by federal agents as part of a price-collusion investigation, causing its stock to drop 6%.
The investigation is related to allegations of price-fixing in the generic drug market, with Perrigo's stock also down 26% since a report highlighted corporate governance issues.
Perrigo has announced a dividend for shareholders, despite the negative news, with some analysts suggesting the DOJ investigation may be an attempt to extort the company.

Macro· Apr 20

Perrigo, a US-based OTC API provider, could benefit from tariffs on imported pharmaceuticals driving domestic production.
Companies with US-based manufacturing, such as Perrigo, may see an increase in demand if tariffs lead to a shift in production from abroad.
Pharmaceutical companies with both domestic and global manufacturing operations, like Pfizer and Merck, may be less impacted by tariffs due to their diversified supply chains.

Technical Analysis· Apr 26

Perrigo Company plc ($PRGO) failed to follow through on momentum, and its price is below its Chandelier Exit of $117.77.
The stock has reached oversold levels, with a 1-month RSI of 21, and is expected to bounce back to $104 before another drop.
Technical indicators, including Expansion Breakdown, Stochastic Reached Oversold, and Wide Range Bar, suggest a potential breakdown in the stock's price, with a target of $89 or lower.

Generated by AI

Community

Of the messages about PRGO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	16%	32.05%	24.94%
Newcomers	0%	84%	67.95%	75.06%

Regulars· Feb 27

Perrigo Company plc has hiked its dividend for the 21st consecutive year, with annual hikes of 1.1%, 5.0%, 8.3%, and 6.7% in the last four years.
Despite reporting better-than-expected financials for Q4 2023, Perrigo's shares lost ~15% on Tuesday due to disappointing outlook amid plans to implement a cost-cutting initiative.
Perrigo reports FQ4 earnings of 86c EPS and $1.16B Revs, but misses the Estimize Revenue Consensus by $17.14M and beats the Estimize EPS Consensus by 4c.

Newcomers· Feb 27

Perrigo Company plc is expecting to lay off approximately 550 employees, roughly 6% of its total staff.
Perrigo has continued its dividend growth streak, marking 21 years of consecutive increases, with a 1.1% hike in 2024.
The company reported Q4 2023 sales missing estimates and guidance for flat reported net sales in 2024, leading to a stock decline of over 15%.

Generated by AI

Perrigo

Social

Aug 5

Bullish· Sep 30

Bearish· Dec 21

Earnings· May 9

Analysts· Sep 30

Announcements· Jul 13

Controversies· May 3

Macro· Apr 20

Technical Analysis· Apr 26

Regulars· Feb 27

Newcomers· Feb 27

Perrigo Co. PLC stock underperforms Monday when compared to competitors

Perrigo Co. PLC stock outperforms competitors on strong trading day

Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last?

Perrigo Co. PLC stock outperforms competitors on strong trading day

Perrigo Co. PLC stock underperforms Wednesday when compared to competitors

Perrigo Co. PLC stock outperforms competitors on strong trading day

Also Discussed

Perrigo Company plc

Company Information

Location

Perrigo Co. PLC stock underperforms Monday when compared to competitors

Perrigo Co. PLC stock outperforms competitors on strong trading day

Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last?

Perrigo Co. PLC stock outperforms competitors on strong trading day

Perrigo Co. PLC stock underperforms Wednesday when compared to competitors

Perrigo Co. PLC stock outperforms competitors on strong trading day

Also Discussed

Social

Aug 5

Bullish· Sep 30

Bearish· Dec 21

Earnings· May 9

Analysts· Sep 30

Announcements· Jul 13

Controversies· May 3

Macro· Apr 20

Technical Analysis· Apr 26

Regulars· Feb 27

Newcomers· Feb 27